Colinz Laboratories ltd.
BSE: COLINZ · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Colinz Laboratories ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Colinz Labs Limited is an Indian pharmaceutical company based in Mumbai that specialises in the manufacturing and marketing of formulations. Its core therapeutic focus areas include gynecology, cardiology, and gastroenterology.
Business Model
The company generates revenue through the ethical promotion of its pharmaceutical brands to medical professionals and the distribution of tablets, capsules, and liquid orals. It leverages its own Good Manufacturing Practices-compliant facility in Maharashtra to provide affordable healthcare solutions.
Growth Outlook
Growth is driven by the company's dedicated field force and its established distribution network within the domestic Indian market. The firm aims to expand its niche presence by focusing on its core therapeutic segments.
Key Risks
- Regulatory Compliance. The company faces risks related to maintaining Good Manufacturing Practices and adhering to evolving pharmaceutical regulations in India.
- Market Competition. As a small-scale player, the company faces intense competition from larger pharmaceutical firms with greater financial resources and wider product portfolios.
- Pricing Pressure. Government-mandated price controls on essential medicines may impact the profit margins of the company's core therapeutic products.
- Operational Concentration. Reliance on a single manufacturing facility in Maharashtra creates a risk of supply chain disruption should the site face operational or regulatory challenges.
Start your research today
Unlock AI insights, financials, peers and live data on Colinz Laboratories ltd. and 5,000+ companies — free.
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Colinz Laboratories ltd.COLINZ | ₹19 Cr | — | — | — | 6.8% | — | — | +86.1% |
Albert DavidALBERTDAVD | ₹513 Cr | 22.73 | 13.48 | 11.4% | 11.0% | 5.8% | 7.5% | +12.1% |
Jenburkt Pharmaceuticals LimitedJENBURPH | ₹463 Cr | 13.31 | 8.46 | — | 32.0% | 17.6% | 23.2% | -4.3% |
Haleos Labs LimitedHALEOSLABS | ₹452 Cr | 28.60 | 12.72 | -3.1% | 13.6% | 7.4% | 10.3% | — |
TranschemTRANSCHEM | ₹424 Cr | 98.76 | 68.07 | -100.0% | 177.7% | 5.3% | 7.0% | +592.6% |
Medicamen BiotecMEDICAMEQ | ₹338 Cr | 33.59 | 15.53 | 24.7% | 11.3% | 4.1% | 6.2% | -27.9% |
As of Mar 2026
Financials
Colinz Laboratories ltd.
BSE: COLINZ · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Colinz Laboratories ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Colinz Labs Limited is an Indian pharmaceutical company based in Mumbai that specialises in the manufacturing and marketing of formulations. Its core therapeutic focus areas include gynecology, cardiology, and gastroenterology.
Business Model
The company generates revenue through the ethical promotion of its pharmaceutical brands to medical professionals and the distribution of tablets, capsules, and liquid orals. It leverages its own Good Manufacturing Practices-compliant facility in Maharashtra to provide affordable healthcare solutions.
Growth Outlook
Growth is driven by the company's dedicated field force and its established distribution network within the domestic Indian market. The firm aims to expand its niche presence by focusing on its core therapeutic segments.
Key Risks
- Regulatory Compliance. The company faces risks related to maintaining Good Manufacturing Practices and adhering to evolving pharmaceutical regulations in India.
- Market Competition. As a small-scale player, the company faces intense competition from larger pharmaceutical firms with greater financial resources and wider product portfolios.
- Pricing Pressure. Government-mandated price controls on essential medicines may impact the profit margins of the company's core therapeutic products.
- Operational Concentration. Reliance on a single manufacturing facility in Maharashtra creates a risk of supply chain disruption should the site face operational or regulatory challenges.
Start your research today
Unlock AI insights, financials, peers and live data on Colinz Laboratories ltd. and 5,000+ companies — free.
Peers · Pharmaceuticals
As of Mar 2026